History and Future of HER2-Targeted Therapy for Advanced Gastric Cancer

被引：7

作者：

Ariga, Shin ^{[1
,2
]}

机构：

[1] Hokkaido Univ, Fac Med, Dept Med Oncol, Sapporo 0608638, Japan

[2] Hokkaido Univ, Grad Sch Med, Sapporo 0608638, Japan

来源：

JOURNAL OF CLINICAL MEDICINE | 2023年 / 12卷 / 10期

关键词：

gastric cancer; HER2; targeted therapy; heterogeneity; METASTATIC BREAST-CANCER; ANTIBODY-DRUG CONJUGATE; DERUXTECAN T-DXD; GASTROESOPHAGEAL JUNCTION; TRASTUZUMAB DERUXTECAN; PHASE-II; MONOCLONAL-ANTIBODY; OPEN-LABEL; PLUS CHEMOTHERAPY; HER-2; RECEPTOR;

D O I：

10.3390/jcm12103391

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Human epidermal growth factor receptor 2 (HER2) is a receptor tyrosine kinase that belongs to the human epidermal growth factor receptor family. It is overexpressed/amplified in approximately 20% of gastric or gastroesophageal junction cancers. HER2 is being developed as a therapeutic target in a variety of cancers, and several agents have been shown to be effective in breast cancer. The development of HER2-targeted therapy for gastric cancer successfully began with trastuzumab. However, while effective in breast cancer, the successive anti-HER2 agents lapatinib, T-DM1, and pertuzumab failed to demonstrate benefits regarding survival in gastric cancer compared with the existing standard therapies. Intrinsic differences lie between gastric and breast cancer in terms of HER2-positive tumor biology, which may make development difficult. Recently, a novel anti-HER2 agent, trastuzumab deruxtecan, was introduced, and the development of HER2-positive gastric cancer agents has been moving to the next stage. This review summarizes the current HER2-targeted therapy for gastric or gastroesophageal cancer in chronological order and describes the promising future of HER2-targeted therapy.

引用

页数：16

共 90 条

[81] Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors [J].

Tsurutani, Junji ;

Iwata, Hiroji ;

Krop, Ian ;

Janne, Pasi A. ;

Doi, Toshihiko ;

Takahashi, Shunji ;

Park, Haeseong ;

Redfern, Charles ;

Tamura, Kenji ;

Wise-Draper, Trisha M. ;

Saito, Kaku ;

Sugihara, Masahiro ;

Singh, Jasmeet ;

Jikoh, Takahiro ;

Gallant, Gilles ;

Li, Bob T. .

CANCER DISCOVERY, 2020, 10 (05) :688-701

[82] Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen [J].

Van Cutsem, E. ;

Di Bartolomeo, M. ;

Smyth, E. ;

Chau, I. ;

Park, H. ;

Siena, S. ;

Lonardi, S. ;

Wainberg, Z. A. ;

Ajani, J. A. ;

Chao, J. ;

Seraj, J. ;

Kawaguchi, Y. ;

Qin, A. ;

Singh, J. ;

Meinhardt, G. ;

Ku, G. .

ANNALS OF ONCOLOGY, 2021, 32 :S1332-S1332

[83] HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer [J].

Van Cutsem, Eric ;

Bang, Yung-Jue ;

Feng-Yi, Feng ;

Xu, Jian M. ;

Lee, Keun-Wook ;

Jiao, Shun-Chang ;

Chong, Jorge Leon ;

Lopez-Sanchez, Roberto I. ;

Price, Timothy ;

Gladkov, Oleg ;

Stoss, Oliver ;

Hill, Julie ;

Ng, Vivian ;

Lehle, Michaela ;

Thomas, Marlene ;

Kiermaier, Astrid ;

Rueschoff, Josef .

GASTRIC CANCER, 2015, 18 (03) :476-484

[84]

Vance GH, 2009, ARCH PATHOL LAB MED, V133, P611, DOI 10.1043/1543-2165-133.4.611

[85] Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer [J].

Verma, Sunil ;

Miles, David ;

Gianni, Luca ;

Krop, Ian E. ;

Welslau, Manfred ;

Baselga, Jose ;

Pegram, Mark ;

Oh, Do-Youn ;

Dieras, Veronique ;

Guardino, Ellie ;

Fang, Liang ;

Lu, Michael W. ;

Olsen, Steven ;

Blackwell, Kim .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (19) :1783-1791

[86] KN026 (anti-HER2 bispecific antibody) in patients with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancer [J].

Xu, Jianming ;

Ying, Jieer ;

Liu, Rongrui ;

Wu, Jun ;

Ye, Feng ;

Xu, Nong ;

Zhang, Yanqiao ;

Zhao, Rusen ;

Xiang, Xiaojun ;

Wang, Jianhong ;

Lin, Xiaoyan ;

Xu, Huiting ;

Gao, Shegan ;

Luo, Suxia ;

Guo, Baohong ;

Li, Xionghui ;

Su, Yangzhi ;

Wang, Qian .

EUROPEAN JOURNAL OF CANCER, 2023, 178 :1-12

[87] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study [J].

Yamaguchi, K. ;

Bang, Y-J. ;

Iwasa, S. ;

Sugimoto, N. ;

Ryu, M-H. ;

Sakai, D. ;

Chung, H. C. ;

Kawakami, H. ;

Yabusaki, H. ;

Lee, J. ;

Saito, K. ;

Kawaguchi, Y. ;

Kamio, T. ;

Kojima, A. ;

Sugihara, M. ;

Shitara, K. .

ANNALS OF ONCOLOGY, 2020, 31 :S899-S900

[88] Untangling the ErbB signalling network [J].

Yarden, Y ;

Sliwkowski, MX .

NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2001, 2 (02) :127-137

[89] AGAPP: efficacy of first-line cisplatin, 5-fluorouracil with afatinib in inoperable gastric and gastroesophageal junction carcinomas. A Hellenic Cooperative Oncology Group study [J].

Zarkavelis, George ;

Samantas, Epaminontas ;

Koliou, Georgia-Angeliki ;

Papadopoulou, Kyriaki ;

Mauri, Davide ;

Aravantinos, Gerasimos ;

Batistatou, Anna ;

Pazarli, Elissavet ;

Tryfonopoulos, Dimitrios ;

Tsipoura, Anna ;

Bobos, Mattheos ;

Psyrri, Amanda ;

Makatsoris, Thomas ;

Petraki, Constantina ;

Pectasides, Dimitrios ;

Fountzilas, George ;

Pentheroudakis, George .

ACTA ONCOLOGICA, 2021, 60 (06) :785-793

[90] Comparison of Treatment Efficacy and Survival Outcomes Between Asian and Western Patients With Unresectable Gastric or Gastro-Esophageal Adenocarcinoma: A Systematic Review and Meta-Analysis [J].

Zhang, Zhening ;

Liu, Zining ;

Chen, Zeyang .

FRONTIERS IN ONCOLOGY, 2022, 12

← 1 2 3 4 5 6 7 8 9 →